TFF Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
TFF Pharmaceuticals's earnings have been declining at an average annual rate of -11.5%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 80.8% per year.
Key information
-11.5%
Earnings growth rate
26.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 80.8% |
| Return on equity | -222.0% |
| Net Margin | -2,894.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?
Apr 10
Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?
Sep 27TFF Pharma: The Potential Is Still Very Much Present
Aug 29TFF Pharmaceuticals: Q3 Data Is Pivotal In So Many Ways
Aug 09TFF Pharmaceuticals expands R&D operations with new Austin facility
Jul 14TFF Pharmaceuticals: A Highly Attractive Basket Of Options
May 23We Think TFF Pharmaceuticals (NASDAQ:TFFP) Needs To Drive Business Growth Carefully
May 17Here's Why We're Not Too Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Situation
Jan 06TFF Pharmaceuticals: Upside Catalysts Starting To Show Up Amid Omicron, But Timidly
Dec 02Companies Like TFF Pharmaceuticals (NASDAQ:TFFP) Are In A Position To Invest In Growth
Sep 16TFF Pharmaceuticals: Cautiously Optimistic
Sep 09TFF Pharma's Platform Is Highly Relevant In The Battle Against The Pandemic
Jul 27TFF Pharmaceuticals: Looking Attractive At These Prices
Jun 03Companies Like TFF Pharmaceuticals (NASDAQ:TFFP) Are In A Position To Invest In Growth
Mar 30How Much Of TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Do Insiders Own?
Feb 23Revenue & Expenses BreakdownBeta
How TFF Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -21 | 11 | 0 |
| 30 Sep 23 | 1 | -24 | 12 | 0 |
| 30 Jun 23 | 1 | -27 | 13 | 0 |
| 31 Mar 23 | 0 | -30 | 14 | 0 |
| 31 Dec 22 | 0 | -32 | 14 | 0 |
| 30 Sep 22 | 0 | -34 | 13 | 0 |
| 30 Jun 22 | 0 | -36 | 13 | 0 |
| 31 Mar 22 | 0 | -32 | 11 | 0 |
| 31 Dec 21 | 0 | -31 | 11 | 0 |
| 30 Sep 21 | 0 | -27 | 10 | 0 |
| 30 Jun 21 | 0 | -23 | 10 | 0 |
| 31 Mar 21 | 0 | -22 | 9 | 0 |
| 31 Dec 20 | 0 | -19 | 8 | 0 |
| 30 Sep 20 | 0 | -41 | 7 | 3 |
| 30 Jun 20 | 0 | -39 | 5 | 6 |
| 31 Mar 20 | 0 | -38 | 4 | 7 |
| 31 Dec 19 | 0 | -37 | 3 | 9 |
| 30 Sep 19 | 0 | -9 | 3 | 6 |
| 30 Jun 19 | 0 | -7 | 3 | 3 |
| 31 Mar 19 | 0 | -7 | 3 | 3 |
| 31 Dec 18 | 0 | -5 | 3 | 1 |
| 30 Sep 18 | 0 | -4 | 2 | 1 |
| 30 Jun 18 | 0 | -3 | 2 | 1 |
| 31 Mar 18 | 0 | 0 | 0 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
Quality Earnings: TFFP is currently unprofitable.
Growing Profit Margin: TFFP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TFFP is unprofitable, and losses have increased over the past 5 years at a rate of 11.5% per year.
Accelerating Growth: Unable to compare TFFP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TFFP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: TFFP has a negative Return on Equity (-222.05%), as it is currently unprofitable.